Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 9/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.54 |
| ▸ | PIM1 | P11309 | 2/20 | 0.54 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.54 |
| ▸ | KDM4A | O75164 | 1/20 | 0.51 |
| ▸ | KDM4B | O94953 | 1/20 | 0.51 |
| ▸ | KDM5C | P41229 | 1/20 | 0.51 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.51 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 1/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 4/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19153580 | 0.85 | PARP1 (0.59) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL669366 | 0.78 | PARP1 (0.59) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL869256 | 0.78 | PARP1 (0.59) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL7970843 | 0.78 | PARP1 (0.59) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL18237710 | 0.77 | PARP1 (0.50) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL6769402 | 0.77 | IP6K1 (0.58) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL21331974 | 0.77 | PARP1 (0.54) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL10121482 | 0.77 | PARP1 (0.62) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL29605527 | 0.74 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3IP6K1 | |
| SCHEMBL1507614 | 0.74 | PARP1 (1.00) | PARP1CHEK1PIM1RPS6KA3IP6K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-6413971-B1 | ANTIPROLIFERATIVE, -CARCINOGENIC, -TUMOR AND -DIABETIC AGENTS; BINDING TO OR MODULATING THE HUMAN KINASE INSERT-DOMAIN-CONTAINING RECEPTOR (KDR) OR THE MURINE FETAL LIVER KINASE 1 (FLK-1) RECEPTOR; VASCULOGENESIS; ANGIOGENESIS | PFIZER INC | 2002-07-02 | — | — | US | disclosed |
| US-6395733-B1 | ANTICANCER AGENTS; ANTIPROLIFERATIVE AGENTS | PFIZER INC | 2002-05-28 | — | — | US | disclosed |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | ARNOLD LEE DANIEL (US) | 2002-04-18 | — | — | US | disclosed |
| EP-0946554-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0831829-A4 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER (US) | 1998-11-25 | — | — | EP | disclosed |
| WO-1998023613-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-06-04 | — | — | WO | disclosed |
| EP-0831829-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040142-A1 | HETEROCYCLIC RING-FUSED PYRIMIDINE DERIVATIVES | PFIZER INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | PARP1 2195/4885CHEK1 628/4885PIM1 1212/4885 |
| US-20020045630-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES | REV1, DPYD, CCNA1 | PARP1 62/4885CHEK1 194/4885PIM1 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.